- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3 - Pairing Patients with the Right Therapies
In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.
In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.
Dr Shafer-Weaver explains that with CTLA-4, melanoma responds well to immunotherapy, but there is work being done currently regarding PD-1 and PD-L1. Results show that even though PD-L1 negative tumor respond well, patients highly express PD-L1 respond better.
“I think the biggest thing right now is there is no consistency in the field, and so I think it is kind of hard right now at this stage to get a grasp on that because we do not have standardized assays that all labs do the same,” she said. “It is not a common thing; specialized labs do that.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
